



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 9/50, 15/57	A1	(11) International Publication Number: WO 92/19729 (43) International Publication Date: 12 November 1992 (12.11.92)
(21) International Application Number: PCT/DK92/00138 (22) International Filing Date: 30 April 1992 (30.04.92) (30) Priority data: 91610036.5 1 May 1991 (01.05.91) EP (34) Countries for which the regional or international application was filed: AT et al. (71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): VON DER OSTEN, Claus [DK/DK]; Boulevarden 14, L66, DK-2800 Lyngby (DK). BRANNER, Sven [DK/DK]; Ved Smedebakken 7A, DK-2800 Lyngby (DK). SVENDSEN, Allan [DK/DK]; Bakkeledet 28, DK-3460 Birkerød (DK). HEDEGÅRD, Lisbeth [DK/DK]; Classensgade 35, 5.t.h., DK-2100 Copenhagen Ø (DK). ERIKSEN, Nina [DK/DK]; Mathildevej 15, L.L.v., DK-2000 Frederiksberg (DK). EGMOND, Maarten, Robert [NL/NL]; De Ness 34, NL-3461 GD Linschoten (NL). CASTELEIJN, Eric [NL/NL]; Palletierburg 105, NL-2907 CG Capelle a/d IJssel (NL).		(74) Common Representative: NOVO NORDISK A/S; Patent Department, Novo Allé, DK-2880 Bagsvaerd (DK). (81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i>
(54) Title: STABILIZED ENZYMES AND DETERGENT COMPOSITIONS (57) Abstract <p>This invention relates to enzymatic detergent compositions comprising novel stabilized proteases, in which naturally occurring amino acid residue (other than proline) has been substituted with a proline residue at one or more positions, at which position(s) the dihedral angles φ (phi) and ψ (psi) constitute values within the intervals $[-90^\circ < \varphi < -40^\circ$ and $-180^\circ < \psi < 180^\circ]$, and which position(s) are not located in regions, in which the protease is characterized by possessing α-helical or β-sheet structure.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland			SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TG	Togo
DE	Germany	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		
ES	Spain	MG	Madagascar		

STABILIZED ENZYMES AND DETERGENT COMPOSITIONS

TECHNICAL FIELD

This invention relates to novel stabilized proteases, nucleotide sequences encoding the stabilized proteases, and host organisms containing the nucleotide sequences encoding the novel stabilized proteases.

BACKGROUND ART

Proteases/Subtilisins

Proteases, or (interchangeably) peptidases, are enzymes that cleave the amide linkages in protein substrates. Bacteria of the *Bacillus* species secrete two extracellular species of protease, a neutral or metalloprotease, and an alkaline protease which is functionally a serine endopeptidase, referred to as subtilisin.

A serine protease is an enzyme which catalyses the hydrolysis of peptide bonds, and in which there is an essential serine residue at the active site [White, Handler and Smith (1973); Principles of Biochemistry; Fifth Edition, McGraw-Hill Book Company, NY, 271-272].

The bacterial serine proteases have molecular weights in the range of 20,000 to 45,000. They hydrolyse simple terminal esters and are similar in activity to eukaryotic chymotrypsin, also a serine protease. A more narrow term, alkaline protease, covering a sub-group, reflects the high pH optimum of some of the serine proteases, from pH 9.0 to 11.0 [for review, see Priest; Bacteriological Rev., 41 711-753 (1977)].

In relation to the present invention a subtilisin is a serine protease produced by Gram-positive bacteria or fungi. According to another definition, a subtilisin is a serine protease, wherein the relative order of the amino acid residues in the catalytic triad is Asp - His - Ser (positions 32, 64, and 221). A wide variety of subtilisins has been identified, and the amino acid sequences of a number of subtilisins have been determined. These include among others six subtilisins from *Bacillus* strains, namely, subtilisin 168, subtilisin BPN', subtilisin Carlsberg, subtilisin

DY, subtilisin amylosacchariticus, and mesentericopeptidase [Kurihara et al. (1972); J. Biol. Chem.; 247 5629-5631; Wells et al. (1983); Nucleic Acids Res.; 11 7911-7925; Stahl and Ferrari (1984); J. Bacteriol.; 159 811-819; Jacobs et al. (1985); Nucl. Acids Res.; 13 8913-8926; Nedkov et al. (1985); Biol. Chem. Hoppe-Seyler; 366 421-430; Svendsen et al. (1985); FEBS LETTERS; 196 228-232] one subtilisin from an actinomycetales, Thermitase from *Thermoactinomyces vulgaris* [Meloun et al. (1985); FEBS LETTERS; 1983 195-200], and one fungal subtilisin, proteinase K from *Tritirachium album* [Jany and Mayer (1985); Biol. Chem. Hoppe-Seyler; 366 584-492].

Proteases such as subtilisins have found much utility in industry, particularly in detergent formulations, as they are useful for removing proteinaceous stains.

The Structure of Proteins

Proteases are globular proteins and quite compact due to the considerable amount of folding of the long polypeptide chain. The polypeptide chain essentially consists of the "backbone" and its "side-groups". As the peptide bond is planar, only rotations around the C_α -N axis and the C_α -C' axis are permitted. Rotation around the C_α -N bond of the peptide backbone is denoted by the torsion angle ϕ (phi), rotation around the C_α -C' bond by ψ (psi) [vide e.g. Creighton, T.E. (1984); Proteins; W.H. Freeman and Company, New York]. The choice of the values of these angles of rotation is made by assigning the maximum value of $+180^\circ$ (which is identical to -180°) to the maximally extended chain. In the fully extended polypeptide chain, the N, C_α and C' atoms are all "trans" to each other. In the "cis" configuration, the angles ϕ and ψ are assigned the value of 0° . Rotation from this position around the bonds so that the atoms viewed behind the rotated bond move "counterclockwise" is assigned negative values by definition, those "clockwise" are assigned positive values. Thus, the values of the torsion angles lie within the range -180° to $+180^\circ$.

Since the C_α -atoms are the swivel point for the chain, the side-groups (R-groups) associated with the C_α -atoms become extremely important with respect to the conformation of the molecule.

The term "conformation" defines the participation of the secondary and tertiary structures of the polypeptide chains in moulding the overall structure of a protein. The correct conformation of a protein is of prime importance to the specific structure of a protein and contributes greatly to the unique catalytic properties (i.e. activity and specificity) of enzymes and their stability.

The amino acids of polypeptides can be divided into four general groups: nonpolar, uncharged polar, and negatively or positively charged polar amino acids. A protein molecule, when submerged in its aqueous environment in which it normally occurs, tends to expose a maximum number of its polar side-groups to the surrounding environment, while a majority of its nonpolar side groups is oriented internally. Orientation of the side-groups in this manner leads to a stabilization of protein conformation.

Proteins, thus, exist in a dynamic equilibrium between a folded and ordered state, and an unfolded and disordered state. This equilibrium in part reflects the short range interactions among the different segments of the polypeptide chain, which tends to stabilize the overall structure of proteins. Thermodynamic forces simultaneously tend to promote randomization of the unfolding molecule.

A way to engineer stabilized proteins is to reduce the extent of unfolding by decreasing the flexibility of the polypeptide backbone, and simultaneously decreasing the entropy of the unfolded chain. So far only few attempts have been made to implement this rationale in the development of novel stabilized proteases.

A general principle of increasing protein thermostability has been provided [Suzuki, Y. (1989); Proc. Japan Acad.; 65 Ser. B]. In this article Suzuki states that the thermostability of a globular protein can be enhanced cumulatively to a great extent by increasing the frequency of proline occurrence at the second site of β -turns without significant alterations in the secondary and tertiary structures as well as in the catalytic function of enzymes. The principle is based on various facts and findings, among these the fact that proline residues show a strong tendency to occur preferentially at the second site of β -turns [Levitt, M (1978); Biochemistry; 17 4277-4285; and Chou, P.Y. & Fasman, G.D (1977); J. Mol. Biol.; 115 135-175]. The principle is restricted to insertion of proline into the second site of β -turns in proteins, no other sites are mentioned.

International Patent Publication WO 89/01520 (Cetus Corporation, USA) provides a method for increasing the stability of a protein by decreasing the configurational entropy of unfolding the protein. The method is applied on a *Streptomyces rubiginosus* xylose isomerase, and it involves substitution of an amino acid
5 with proline, or replacement of glycine with alanine, at predicted substitution sites.

In International Patent Publication WO 89/09819 (Genex Corporation, USA) a method for combining mutations for stabilization of subtilisins is provided. This publication lists a number of amino acid mutations that have been found to be thermally stabilizing mutations. The list comprises substitution of serine with proline
10 at position 188 of subtilisins (BPN' numbering).

International Patent Publication WO 87/05050 (Genex Corporation, USA) describes a method for mutagenesis and screening. By this method one or more mutations are introduced by treatment with mutagenizing agents, and the method includes subsequent screening for products with altered properties. As a result of
15 this random mutagenesis a subtilisin with a proline residue at position 188 (BPN' numbering) is provided.

It is an object of this invention to provide novel proteases having improved stability.

SUMMARY OF THE INVENTION

20 The present invention provides novel stabilized proteases, in which a naturally occurring amino acid residue (other than proline) has been substituted with a proline residue at one or more positions, at which position(s) the dihedral angles ϕ (phi) and ψ (psi) constitute values within the intervals $[-90^\circ < \phi < -40^\circ$ and $-180^\circ < \psi < 180^\circ]$, preferably within the intervals $[-90^\circ < \phi < -40^\circ$ and $120^\circ < \psi < 180^\circ]$ or $[-90^\circ < \phi < -40^\circ$ and $-50^\circ < \psi < 10^\circ]$, and which position(s) is/are not located in regions, in which
25 the protease is characterized by possessing α -helical or β -sheet structure.

In another aspect, the invention relates to nucleotide sequences encoding the proteases. In further aspects, the invention relates to an expression vector comprising a nucleotide sequence encoding a protease, and to a host organ-
30 ism containing this expression vector.

Subtilisins

In the context of this invention a subtilisin is defined as a serine protease produced by gram-positive bacteria or fungi. According to another definition, a subtilisin is a serine protease, wherein the relative order of the amino acid residues in the catalytic triad is Asp - His - Ser (positions 32, 64, and 221, BPN' numbering).

Amino Acids

As abbreviations for amino acids the following symbols are used:

	A	=	Ala	=	Alanine
10	C	=	Cys	=	Cysteine
	D	=	Asp	=	Aspartic acid
	E	=	Glu	=	Glutamic acid
	F	=	Phe	=	Phenylalanine
	G	=	Gly	=	Glycine
15	H	=	His	=	Histidine
	I	=	Ile	=	Isoleucine
	K	=	Lys	=	Lysine
	L	=	Leu	=	Leucine
	M	=	Met	=	Methionine
20	N	=	Asn	=	Asparagine
	P	=	Pro	=	Proline
	Q	=	Gln	=	Glutamine
	R	=	Arg	=	Arginine
	S	=	Ser	=	Serine
25	T	=	Thr	=	Threonine
	V	=	Val	=	Valine
	W	=	Trp	=	Tryptophan
	Y	=	Tyr	=	Tyrosine
	B	=	Asx	=	Asp (D) or Asn (N)
30	Z	=	Glx	=	Glu (E) or Gln (Q)
	X	=	an arbitrary amino acid		
	*	=	deletion or absent amino acid		

Protease Variants

A stabilized protease of this invention is a protease variant or mutated protease. By a protease variant or mutated protease is meant a protease obtainable by alteration of a DNA nucleotide sequence of the parent gene or its derivatives. The protease variant or mutated protease may be expressed and produced when the

DNA nucleotide sequence encoding the protease is inserted into a suitable vector in a suitable host organism. The host organism is not necessarily identical to the organism from which the parent gene originated.

Amino Acid Numbering

5 In the context of this invention a specific numbering of amino acid residue positions in subtilisins is employed. By alignment of the amino acid sequences of various subtilisins along with subtilisin BPN', it is possible to allot a number to the amino acid residue position in any subtilisin to the number of the analogous amino acid position in subtilisin BPN' ('BPN' numbering', *vide* e.g. Inter-
10 national Patent Publications Nos. WO 89/06279 and WO 91/00345).

In describing the various protease variants produced or contemplated according to the invention, the following nomenclatures were adapted for ease of reference:

[Original amino acid; Position; Substituted amino acid]

15 Accordingly, the substitution of alanine with proline in position 195 is designated as:

A195P

Deletion of an aspartic acid at position 36 is indicated as: D36*, and an insertion in such a position is indicated as: 36D for insertion of an aspartic acid
20 in position 36.

Multiple mutations are separated by plusses, i.e.:

A194P+G195E

representing mutations in positions 194 and 195 substituting alanine with proline and glycine with glutamic acid, respectively.

25 If a substitution is made by mutation in e.g. subtilisin 309, the product is designated e.g. "subtilisin 309/G195E".

All positions mentioned in this context refer to the BPN' numbers described above.

Proteolytic Activity

In the context of this invention proteolytic activity is expressed in Kilo NOVO Protease Units (KNPU). The activity is determined relatively to an enzyme standard (SAVINASE™), and the determination is based on the digestion of a dimethyl casein (DMC) solution by the proteolytic enzyme at standard conditions, i.e. 50°C, pH 8.3, 9 min. reaction time, 3 min. measuring time. A folder AF 220/1 is available upon request to Novo Nordisk A/S, Denmark, which folder is hereby included by reference.

Wash Performance

The ability of an enzyme to catalyse the degradation of various naturally occurring substrates present on the objects to be cleaned during e.g. wash is often referred to as its washing ability, washability, detergency, or wash performance. Throughout this application the term wash performance will be used to encompass this property.

BRIEF DESCRIPTION OF DRAWINGS

The present invention is further illustrated by reference to the accompanying drawings, in which:

Fig. 1 (sheets 1/20 - 15/20) shows the construction of a synthetic gene;
and

Fig. 2 (sheets 16/20 - 20/20) shows the residual activity of subtilisin 309 variants compared to wild type enzyme after storage in a liquid detergent.

DETAILED DISCLOSURE OF THE INVENTION

The present invention provides novel stabilized proteases, in which a naturally occurring amino acid residue (other than proline) has been substituted with a proline residue at one or more positions, at which position(s) the dihedral angles ϕ (phi) and ψ (psi) constitute values in the intervals $[-90^\circ < \phi < -40^\circ$ and $-180^\circ < \psi < 180^\circ]$, preferably the intervals $[-90^\circ < \phi < -40^\circ$ and $120^\circ < \psi < 180^\circ]$ or $[-90^\circ < \phi < -40^\circ$

and $-50^\circ < \psi < 10^\circ$], and which position(s) is/are not located in regions, in which the protease is characterized by possessing α -helical or β -sheet structure.

In the context of this invention, a stabilized protease is a protease variant or mutated protease, being functionally equivalent or having structural features similar to a naturally occurring protease, and in which protease a naturally occurring amino acid residue (other than proline) has been substituted with a proline residue at one or more positions, at which position(s) the dihedral angles ϕ (phi) and ψ (psi) constitute values within the intervals $[-90^\circ < \phi < -40^\circ$ and $-180^\circ < \psi < 180^\circ]$, preferably the intervals $[-90^\circ < \phi < -40^\circ$ and $120^\circ < \psi < 180^\circ]$ or $[-90^\circ < \phi < -40^\circ$ and $-50^\circ < \psi < 10^\circ]$, and which position(s) is/are not located in regions, in which the protease is characterized by possessing α -helical or β -sheet structure.

Moreover, in the context of this invention, a stabilized protease is a protease having improved stability, e.g. in respect to thermal stability, storage stability, etc., when compared to the parent enzyme.

15 Defining Secondary Structure of Proteins

The stabilized proteases of the invention may be obtained by subjecting the protease in question to analysis for secondary structure, identifying residues in the protease having dihedral angles ϕ (phi) and ψ (psi) confined to the intervals $[-90^\circ < \phi < -40^\circ$ and $-180^\circ < \psi < 180^\circ]$, preferably the intervals $[-90^\circ < \phi < -40^\circ$ and $120^\circ < \psi < 180^\circ]$ or $[-90^\circ < \phi < -40^\circ$ and $-50^\circ < \psi < 10^\circ]$, excluding residues located in regions in which the protease is characterized by possessing α -helical or β -sheet structure, if a proline residue is not already at the identified position(s), substitution of the naturally occurring amino acid residue with a proline residue at the identified position(s), preferably by site directed mutagenesis applied on a gene encoding the protease in question, and gene expression by insertion of the gene encoding the stabilized protease in a suitable host organism, followed by cultivation of said host organism in a suitable nutrient medium, and recovery of the desired protease.

This preparation includes subjecting the protease in question to analysis for secondary structure. To perform such analysis the atomic structure of the protease has to be elucidated. The atomic structure can be determined by X-ray diffraction techniques. X-ray diffraction techniques are described by e.g. Hendrick-

son, W.A [X-ray diffraction; in Protein Engineering (Ed: Oxender, D.L and Fox, C.F.), ch. 1; Alan R. Liss, Inc. (1987)] and Creighton, T.E., *supra*, ch. 6.

The crystal structure of Subtilisin 309 has been deduced [*vide* Betzel, B., Klupsch, S., Papendorf, G., Hastrup, S., Branner, S., and Wilson, K.S. (1992); J. Mol. Biol. **223** 427-445], and the coordinates have been deposited and are available from the Brookhaven Protein Data Bank [Bernstein *et al.* (1977); J. Mol. Biol. **112** 535-542].

When the atomic structure has been determined, it is possible to compute dihedral angles from the atomic coordinates. Moreover, it is possible to assign secondary structure elements. The secondary structure elements are defined on the basis of hydrogen bindings. Cooperative secondary structure is recognized as repeats of the elementary hydrogen-bonding patterns "turn" and "bridge". Repeating turns are "helices", repeating bridges are "ladders", connected ladders are "sheets".

Analysis for secondary structure elements requires a computerized compilation of structure assignments and geometrical features extracted from atomic coordinates. The conventional method to elucidate the secondary structure of a protein, based on its atomic coordinates, is described by Kabsch, W. and Sander, C. [Biopolymers (1983) **22** 2577-2637]. In this article an algorithm for extracting structural features from the atomic coordinates by a pattern-recognition process is provided. First, H-bonds are identified based on electrostatic interactions between pairs of H-bonding groups. Next, the patterns of H-bonding are used to define secondary structure elements such as turns (T), bends (S), bridges (B), helices (G,H,I), β -ladders (E) and β -sheets (E).

A computer program DSSP (Define Secondary Structure of Proteins), enabling the computation of Kabsch & Sander files and written in standard PASCAL, is available from the Protein Data Bank, Chemistry Dept., Brookhaven National Laboratory, Upton, N.Y. 11973.

After the dihedral angles ϕ (phi) and ψ (psi) for the amino acids have been calculated, based on the atomic structure in the crystalline proteases, it is possible to select position(s) which has/have dihedral phi and psi angles favourable for substitution with a proline residue. The aliphatic side chain of proline residues is

bonded covalently to the nitrogen atom of the peptide group. The resulting cyclic five-membered ring consequently imposes a rigid constraint on the rotation about the N-C α bond of the peptide backbone and simultaneously prevents the formation of hydrogen bonding to the backbone N-atom. For these structural reasons, prolines are generally not compatible with α -helical and β -sheet secondary conformations. Due to the same rotational constraint about the C α -N bond, and due to the requirement that neighbouring amino acids in the chain are not perturbed, the magnitudes of the dihedral angles phi and psi (and in particular phi) are confined to limited intervals for proline residues in polypeptides. The dihedral angles for proline residues in polypeptides are almost exclusively within the intervals $[-90^\circ < \phi < -40^\circ$ and $-180^\circ < \psi < 180^\circ]$, preferably the intervals $[-90^\circ < \phi < -40^\circ$ and $120^\circ < \psi < 180^\circ]$ or $[-90^\circ < \phi < -40^\circ$ and $-50^\circ < \psi < 10^\circ]$. In this context, both cis- and trans-proline residues are considered.

A proline residue may already occur at one or more positions pointed out by the procedure described above, and then a substitution is, of course, irrelevant. Otherwise, the method includes substitution of the naturally occurring amino acid residue with a proline residue.

However, a substitution into proline at every of the predicted positions may not always bring about improved thermostability of the protease. At some of the positions revealed by this method, a substitution of a naturally occurring amino acid residue into a proline residue may even cause destabilisation due to unpredictable factors, such as loss of essential flexibility, loss of H-bond possibilities, unpredictable sterical hindrance, etc. Such "critical sites" are not to be foreseen.

It is to be expected that the stabilizing (or destabilizing) effects of individual substitutions are additive, *vide e.g. Wells, J.A. [Biochemistry (1990) 29 (37) 8510-8517]* and Table 4, below.

If a subtilisin different from subtilisin 309 is subjected to this method (although the two subtilisins may seem very much similar), not necessarily the same number of positions, nor particularly the identical positions, may result from the method. It is likely that some of the positions may be identical, and it is likely that the numbers of positions are of equal magnitude, but it is not to be foreseen.

However, it seems likely that the stabilizing proline substitutions resulting from the above described method, applied to any specific protease, may also have a stabilizing effect on any other protease, independent of the result of the above described method applied to such a protease.

5 When performing the method on a subtilisin 309 molecule (*vide* International Patent Application No. PCT/DK88/00002), a set of data as listed in Tables 1 and 2 can be obtained. Table 1 depicts a set of positions that - with respect to phi and psi angles - meet one criterion, and Table 2 depicts an additional set of positions that meet another criterion.

10 Table 1

Proline Mutants Proposed in Subtilisin 309 Based on phi and psi Angles.

Criteria: $-90^\circ < \phi < -40^\circ$ and $120^\circ < \psi < 180^\circ$, or
 $-90^\circ < \phi < -40^\circ$ and $-50^\circ < \psi < 10^\circ$.
 Neither part of an alpha helix nor a beta sheet structure.

15 BPN' numbers	phi angle	psi angle	Amino acid	Structure	Mutant & Comments
5	-59	148	P		Pro already in Subt.309
11	-80	-1	V	T	
20 19	-85	1	R	T	
24	-57	132	S	T	
33	-79	10	T	S	
37	-89	145	S		
38	-58	146	T		
25 40	-60	-27	P	T	Pro already in Subt.309
52	-59	131	P	T	Pro already in Subt.309
55	-71	-22	P		Pro already in Subt.309
57	-90	167	S	S	
59	-60	151	Q		
30 74	-57	141	A		
75	-67	148	L		
83	-81	173	G		
84	-72	-35	V	S	
86	-59	-12	P	T	Pro already in Subt.309
35 88	-68	152	A		

	97	-73	174	G		
	98	-57	-32	A	T	
	99	-67	-12	S	T	
	119	-70	149	M		
5	129	-68	-24	P	S	Pro already in Subt.309
	130	-85	126	S	S	
	131	-63	156	P		Pro already in Subt.309
	145	-88	10	R	T	
	147	-86	134	V		
10	153	-74	-20	S		
	156	-82	-11	S	S	
	158	-70	159	A		
	163	-66	166	S		
	169	-52	-33	A	T	
15	170	-66	-21	R	T	
	171	-67	141	Y	S	
	172	-52	-43	A	T	
	173	-79	1	N	T	
	182	-63	-16	Q	T	
20	186	-65	133	R	B	
	187	-65	151	A		
	188	-64	-27	S	T	
	189	-77	-17	F	T	
	191	-69	151	Q		
25	194	-56	130	A	T	
	210	-53	155	P	T	Pro already in Subt.309
	239	-58	-25	P	T	Pro already in Subt.309
	241	-79	149	W		
	242	-86	178	S		
30	254	-71	165	A	S	
	256	-59	136	S		
	259	-48	131	S		
	265	-69	-20	S	T	
	267	-79	127	L	B	
35	268	-58	141	V		

By relaxing the constraint on the psi angle relative to the criteria set up in Table 1, four additional mutants are proposed, *vide* Table 2.

Table 2

Proline Mutants Proposed in Subtilisin 309 based on phi and psi Angles.

Relaxed criteria: $-90^\circ < \phi < -40$ and $-180^\circ < \psi < 180$.

Neither part of an alpha helix nor a beta sheet structure.

5

BPN' numbers	phi angle	psi angle	Amino acid	Structure	Mutant & Comments
76	-89	102	N	S	
10 125	-90	67	S		
160	-83	27	G	S	
255	-89	111	T	B	

Preferred Stabilized Proteases

15

Preferably, a protease of the invention is a stabilized subtilisin protease. In a more specific aspect, a preferred protease of the invention is a subtilisin, in which the stabilized subtilisin obtained is any subtilisin which comprises a substitution into a proline residue at one or more of the positions listed in Tables 1 and 2 (BPN' numbers), or positions analogous hereto.

20

In a more specific aspect, a proteases of the invention is a subtilisin in which a naturally occurring amino acid (other than proline) has been substituted with a proline residue at one or more of the positions: 38, 57, 98, 172, 188, 194, 242, and 259 (BPN' numbers). In further preferred embodiments, the subtilisin in addition comprises one or more of the following substitutions: 27R, 36D, 76D, 97N, 98R, 104Y, 120D, 128G, 195E, 206C, 218S, 235L, 235R, 237R, 251E, and 263F (BPN' numbers).

25

In a yet more specific aspect, the protease of the invention is a stabilized subtilisin 309, a stabilized subtilisin 147, a stabilized subtilisin BPN', or a stabilized subtilisin Carlsberg. Subtilisin 309 and Subtilisin 147 are variants of *Bacillus* 30 *lentus* and described in US Patent No. 3,723,250 and International Patent Application PCT/DK 88/00002, Subtilisin BPN' is described by Wells *et al.* [Nucleic Acids Res. (1983) 11 7911-7925]; Subtilisin Carlsberg is described by Smith *et al.* [Smith, E.L.;

DeLange, R.J.; Evans, W.H.; Landon, W.; Markland, F.S. (1968); Subtilisin Carlsberg V. The complete sequence: comparison with subtilisin BPN'; Evolutionary relationships.; *J. Biol. Chem.* 243 (9) 2184-2191), and *Jacobs et al.* [*Nucl. Acids Res.* (1985) 13 8913-8926].

5 In another specific aspect, a protease of the invention is a stabilized subtilisin 309 in which one or more of the following substitutions have been introduced: T38P, S57P, A98P, S188P, A172P, A194P, S242P, and S259P (BPN' numbers). In further preferred embodiments, this subtilisin in addition comprises one or more of the following substitutions: K27R, *36D, N76D, G97N, A98R, V104Y, H120D,
10 S128G, G195E, Q206C, N218S, K235L, K235R, K237R, K251E, and Y263F (BPN' numbers).

In yet another preferred embodiment, the protease of the invention is a subtilisin 309, in which one or more of the following substitutions have been introduced: T38P, S57P, A98P, A172P, A194P, S242P, and S259P (BPN' numbers). In a
15 further preferred embodiment, this subtilisin 309 in addition comprises one or more of the following substitutions: K27R, *36D, N76D, G97N, A98R, V104Y, H120D, S128G, G195E, Q206C, N218S, K235L, K235R, K237R, K251E, and Y263F (BPN' numbers).

Most preferred proteases of the invention are: Subtilisin 309/K27R+-
20 *36D+G97N+A98R+A194P+K235R+K237R+K251E+Y263F, Subtilisin 309/K27R+-
*36D+G97N+A194P+K235R+K237R+K251E+Y263F, Subtilisin 309/K27R+*36D+-
G97N+A194P+K235R+K237R+Y263F, Subtilisin 309/*36D+N76D+H120D+A1-
94P+G195E+K235L, Subtilisin 309/*36D+G97N+V104Y+H120D+A194P+G195E,
Subtilisin 309/*36D+G97N+V104Y+H120D+A194P+G195E+K235L, Subtilisin
25 309/*36D+G97N+H120D+A194P+G195E, Subtilisin 309/*36D+G97N+H120D-
+A194P+G195E+K235L, Subtilisin 309/*36D+V104Y+H120D+A194P+G195E,
Subtilisin 309/*36D+V104Y+H120D+A194P+G195E+K235L, Subtilisin 309/*36D-
+H120D+A194P+G195E, Subtilisin 309/*36D+H120D+A194P+G195E+K235L and
Subtilisin 309/A194P (BPN' numbers).

The Effect of Proline Stabilization

The purified variants obtained according to this invention have been tested to wash at least equally well compared to the wild-type subtilisin (subtilisin 309), *vide* Example 5 for experimental data.

5 The storage stability generally reflects the thermostability, i.e. improved thermostability corresponds with improved storage stability. The improvement in thermostability of purified variants has been tested by a differential scanning calorimetry (DSC) method, *vide* Example 3 for experimental data. The result of these tests is shown in Table 3, below. The storage stability has been tested by a Mini Storage
10 Test, *vide* Example 4 for experimental data, and the results of the storage stability test are shown in Fig. 2.

Table 3

Stabilization relative to Subtilisin 309

15	Variant	Relative stabilization Δ DSC (°C)
20	S24P	-2.0 °C
	T38P	-0.1 °C
	S57P	0.7 °C
	A98P	0.1 °C
	S99P	-0.2 °C
	A172P	0.1 °C
25	Q182P	-2.5 °C
	S188P	1.5 °C
	A194P	2.6 °C
	S242P	1.4 °C
	S256P	-2.1 °C
30	S259P	0.6 °C

It appears from Table 3 that 3 of the variants constructed possess significantly improved thermostability, 2 of the variants possess only slightly improved thermostability, 4 of the variants possess no significant change in thermosta-

bility, and 3 of the variants possess significantly decreased thermostability, when compared to the wild-type enzyme.

These results demonstrate that although a clear rationale exists for stabilization by introduction of proline residues into a protein by the Phi-Psi-Concept
5 described in this specification, no conclusion as to the stabilizing effect of the individual variants is predictable.

However, when a variant with improved thermostability has been obtained, the stabilizing effect of individual mutations in general is considered additive. This is demonstrated in Table 4 below, where the thermal denaturation
10 temperatures, as measured by differential scanning calorimetry (DSC), of Subtilisin 309 variants relative to the wild-type enzyme are presented.

Thus, stabilized protease variants which, further to the stabilizing proline residue(s) inserted, contain one or more additional stabilizing mutations as described in this specification, are considered within the scope of this invention.

Table 4

Additive Stabilizing Effect in Subtilisin 309 Variants

Figures in parenthesis indicate the sum of Δ DSC temperatures for variants tested individually.

Variants		Δ DSC (°C)
5	G195E	0.1
10	H120D	0.2
	K235L	0.0
	*36D	4.0
	N76D	4.3
	A194P	2.6
15	G97N	-0.3
	V104Y	2.3
	G195E H120D K235L	0.3 (0.3)
	G195E H120D K235L *36D	4.0 (4.3)
	G195E H120D K235L *36D A194P	7.0 (6.9)
20	G195E H120D K235L *36D N76D	7.0 (8.6)
	G195E H120D K235L *36D N76D A194P	10.4 (11.2)
	G195E H120D *36D A194P G97N	7.4 (6.6)
	G195E H120D *36D A194P G97N V104Y	8.2 (8.2)
	G195E H120D K235L *36D A194P G97N	6.9 (6.6)
25	G195E H120D K235L *36D A194P G97N V104Y	8.0 (8.9)

Method For Producing Mutations In Genes Encoding Proteases

Many methods for introducing mutations into genes are well known in the art. After a brief discussion of cloning subtilisin genes, methods for generating mutations at specific sites within the subtilisin gene will be discussed.

Cloning A Subtilisin Gene

The gene encoding subtilisin may be cloned from any Gram-positive bacteria or fungus by various methods, well known in the art. First a genomic, and/or cDNA library of DNA must be constructed using chromosomal DNA or messenger RNA from the organism that produces the subtilisin to be studied. Then, if the amino-acid sequence of the subtilisin is known, homologous, oligonucleotide probes may be synthesized, labelled, and used to identify subtilisin-encoding clones from a

genomic library of bacterial DNA, or from a fungal cDNA library. Alternatively, a labelled oligonucleotide probe containing sequences homologous to subtilisin from another strain of bacteria or fungus could be used as a probe to identify subtilisin-encoding clones, using hybridization and washing conditions of lower stringency.

5 Yet another method for identifying subtilisin-producing clones would involve inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming protease-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing a substrate for subtilisin, such as skim-milk. Those bacteria containing subtilisin-bearing plasmid
10 will produce colonies surrounded by a halo of clear agar, due to digestion of the skim-milk by excreted subtilisin.

Generation Of Site Directed Mutations In The Subtilisin Gene

Once the subtilisin gene has been cloned, and desirable sites for mutagenesis identified, the mutations can be introduced using synthetic oligo-
15 nucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites, mutant nucleotides are inserted during oligonucleotide synthesis. In a preferred method, a single stranded gap of DNA, bridging the subtilisin gene, is created in a vector bearing the subtilisin gene. Then the synthetic nucleotide, bearing the desired mutation, is annealed to a homologous portion of the
20 single-stranded DNA. The remaining gap is then filled in by DNA polymerase I (Klenow fragment) and the construct is ligated using T4 ligase. A specific example of this method is described [Morinaga et al. (1984); Biotechnology, 2 646-639]. According to Morinaga et al., a fragment within the gene is removed using restriction endonuclease. The vector/gene, now containing a gap, is then denatured and hy-
25 bridized to a vector/gene which, instead of containing a gap, has been cleaved with another restriction endonuclease at a site outside the area involved in the gap. A single-stranded region of the gene is then available for hybridization with mutated oligonucleotides, the remaining gap is filled in by the Klenow fragment of DNA polymerase I, the insertions are ligated with T4 DNA ligase, and, after one cycle of
30 replication, a double-stranded plasmid bearing the desired mutation is produced. The Morinaga method obviates the additional manipulation of constructing new

restriction sites, and, therefore, facilitates the generation of mutations at multiple sites. US Patent No. 4,760,025, by *Estell et al.*, issued July 26, 1988, is able to introduce oligonucleotides bearing multiple mutations by performing minor alterations of the cassette, however, an even greater variety of mutations can be introduced at
5 any one time by the Morinaga method, because a multitude of oligonucleotides, of various lengths, can be introduced.

Expression Of Subtilisin Variants

According to the invention, a mutated subtilisin gene produced by methods described above, by the method described in Example 1, or any alternative
10 methods known in the art, can be expressed, in enzyme form, using an expression vector. An expression vector generally falls under the definition of a cloning vector, since an expression vector usually includes the components of a typical cloning vector, namely, an element that permits autonomous replication of the vector in a microorganism independent of the genome of the microorganism, and one or more
15 phenotypic markers for selection purposes. An expression vector includes control sequences encoding a promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a repressor gene or various activator genes.

To permit the secretion of the expressed protein, nucleotides encoding a "signal sequence" may be inserted prior to the coding sequence of the gene. For
20 expression under the direction of control sequences, a target gene to be treated according to the invention is operably linked to the control sequences in the proper reading frame. Promoter sequences that can be incorporated into plasmid vectors, and which can support the transcription of the mutant subtilisin gene, include but are not limited to the prokaryotic β -lactamase promoter [*Villa-Komaroff, et al.* (1978);
25 *Proc. Natl. Acad. Sci. U.S.A.*; **75** 3727-3731] and the tac promoter [*DeBoer, et al.* (1983); *Proc. Natl. Acad. Sci. U.S.A.*; **80** 21-25]. Further references can also be found in "Useful proteins from recombinant bacteria" in *Scientific American* (1980); **242** 74-94.

According to one embodiment, *B. subtilis* is transformed by an expres-
30 sion vector carrying the mutated DNA. If expression is to take place in a secreting microorganism such as *B. subtilis* a signal sequence may follow the translation initia-

tion signal and precede the DNA sequence of interest. The signal sequence acts to transport the expression product to the cell wall where it is cleaved from the product upon secretion. The term "control sequences" as defined above is intended to include a signal sequence, when it is present.

5 The microorganisms able to produce a stabilized enzyme of this invention can be cultivated by conventional fermentation methods in a nutrient medium containing assimilable carbon and nitrogen together with other essential nutrients, the medium being composed in accordance with the principles of the known art.

10 Nucleotide Sequences And Microorganisms

This invention also relates to DNA nucleotide sequences encoding a stabilized protease of the invention, and to an expression vector containing a DNA nucleotide sequence encoding a stabilized protease.

15 The stabilized protease may be expressed and produced when DNA nucleotide sequence encoding this protease is inserted into a suitable expression vector in a suitable host organism. The host organism is not necessarily identical to the organism from which the parent gene originated. The construction of the mutated genes, vectors and mutant and transformed microorganisms may be carried out by any appropriate recombinant DNA technique, known in the art.

20 The invention also relates to host organisms containing an expression vector carrying a DNA nucleotide sequence encoding a stabilized protease.

Detergent Compositions

25 The present invention also comprises the use of the stabilized proteases of the invention in cleaning and detergent compositions and such composition comprising the stabilized proteases.

Such compositions comprise any one or more of the proteases of the invention alone or in combination with any of the usual components included in such compositions which are well-known to the person skilled in the art.

30 Such components comprise builders, such as phosphate or zeolite builders, surfactants, such as anionic, cationic, non-ionic or zwitterionic type surfac-

tants, polymers, such as acrylic or equivalent polymers, bleach systems, such as perborate- or amino-containing bleach precursors or activators, structurants, such as silicate structurants, alkali or acid to adjust pH, humectants, and/or neutral inorganic salts.

5 The detergent compositions of the invention can be formulated in any convenient form such as powders, liquids, etc.

 The enzymes can be used in well-known standard amounts in detergent compositions. The amounts may range very widely, e.g. about 0.0002-0.01, e.g. about 0.005-0.05, Anson units per gram of the detergent composition. Expressed in
10 alternative units, the protease can be included in the compositions in amounts in the order of from about 0.1 to 100 GU/mg (e.g. 1-50, especially 5-20 GU/mg) of the detergent formulation, or any amount in a wide range centering at about 0.01-4, e.g. 0.1-0.4 KNPU per g of detergent formulation.

 The KNPU has been defined previously. A GU is a Glycine Unit, defined
15 as the proteolytic enzyme activity which, under standard conditions, during a 15-minutes' incubation at 40 deg C, with N-acetyl casein as substrate, produces an amount of NH₂-group equivalent to 1 micromole of glycine.

 It may for example be suitable to use the present enzymes at the rate of about 0.25 mg of enzyme protein per litre of wash liquor, corresponding to an
20 enzyme activity of the order of 0.08 KNPU per litre. Corresponding detergent formulations can contain the enzymes in for example an amount of the order of 0.1-0.4 KNPU/g.

 The detergent compositions may also contain further enzymes.

 For example, lipase can usefully be added in the form of a granular
25 composition (alternatively a solution or a slurry) of lipolytic enzyme with carrier material (e.g. as in EP Patent Publication No. 258,068 (Novo Nordisk A/S) and the Lipolase™ and other enzyme compositions of Novo Nordisk A/S).

 The added amount of lipase can be chosen within wide limits, for example 50 to 30,000 LU/g per gram of the surfactant system or of the detergent
30 composition, e.g. often at least 100 LU/g, very usefully at least 500 LU/g, sometimes preferably above 1000, above 2000 LU/g or above 4000 LU/g or more, thus very often within the range of 50-4000 LU/g, and possibly within the range of 200-1000

LU/g. In this specification, lipase units are defined as they are in EP Patent Publication No. 258,068.

The lipolytic enzyme can be chosen among a wide range of lipases. In particular, the lipases described in for example the following patent specifications:
5 EP Patent Publications Nos. 214,761 (Novo Nordisk A/S), 258,068, and especially lipases showing immunological crossreactivity with antisera raised against lipase from *Thermomyces lanuginosus* ATCC 22070, EP Patent Publications Nos. 205,208 and 206,390, and especially lipases showing immunological cross-reactivity with antisera raised against lipase from *Chromobacter viscosum* var *lipolyticum* NRRL
10 B-3673, or against lipase from *Alcaligenes* PL-679, ATCC 31371 and FERM-P 3783, also the lipases described in specifications WO 87/00859 (Gist-Brocades) and EP Patent Publication No. 204,284 (Sapporo Breweries). Suitable, in particular, are for example the following commercially available lipase preparations: Lipolase Novo Nordisk A/S, Amano lipases CE, P, B, AP, M-AP, AML, and CES, and Meito lipases
15 MY-30, OF, and PL, also Esterase MM, Lipozym, SP225, SP285, Saiken lipase, Enzeco lipase, Toyo Jozo lipase and Diosynth lipase (Trade Marks).

Amylase can for example be used when desired, in an amount in the range of about 1 to about 100 MU (maltose units) per gram of detergent composition (or 0.014-1.4, e.g. 0.07-0.7, KNU/g (Novo units)). Cellulase can for example
20 be used when desired, in an amount in the range of about 0.3 to about 35 CEVU units per gram of the detergent composition.

Among the usual detergent ingredients which may be present in usual amounts in the detergent compositions of this invention are the following: The compositions may be built or unbuilt, and may be of the zero-P type (i.e. not
25 containing any phosphorus containing builders). Thus, the composition may contain in the aggregate for example from 1-50%, e.g. at least about 5% and often up to about 35-40% by weight, of one or more organic and/or inorganic builders. Typical examples of builders include those already mentioned above, and more broadly include alkali metal ortho, pyro, and tripolyphosphates, alkali metal carbonates, either
30 alone or in admixture with calcite, alkali metal citrates, alkali metal nitrilotriacetates, carboxymethyloxysuccinates, zeolites, polyacetalcarboxylates, and so on.

Furthermore, the detergent compositions may contain from 1-35% of a bleaching agent or a bleach precursor or a system comprising bleaching agent and/or precursor with activator therefor. Further optional ingredients are lather boosters, foam depressors, anti-corrosion agents, soil-suspending agents, sequestering agents, anti-soil redeposition agents, perfumes, dyes, stabilising agents for the enzymes, and so on.

The compositions can be used for the washing of textile materials, especially, but without limitation cotton and polyesterbased textiles and mixtures thereof. For example washing processes carried out at temperatures of about 60-65°C or lower, e.g. about 30-35°C or lower, are particularly suitable. It can be very suitable to use the compositions at a rate sufficient to provide about e.g. 0.4-0.8 g/l of surfactant in the wash liquor, although it is of course possible to use lower or higher concentrations, if desired. Without limitation it can for example be stated that a use-rate from about 1 to 10 g/l, e.g. from about 3-6 g/l, of the detergent formulation is suitable for use in the case when the formulations are substantially as in the Examples.

In some useful embodiments, the detergent compositions can be formulated as follows:

Detergent I:

A detergent powder according to an embodiment of the invention containing zeolite builder is formulated to contain:

Total active detergent of about 16%, anionic detergent of about 9%, nonionic detergent of about 6%, zeolite-containing builder of about 20%, acrylic or equivalent polymer of about 3.5%, perborate bleach precursor of about 6-18%, amino-containing bleach activator of about 2%, silicate or other structurant of about 3.5%, alternatively down to about 2.5%, enzyme of about 8 (alternatively of about 15) glycine units/mg grade, with alkali to adjust to desired pH in use, and neutral inorganic salt, and enzymes (about 0.5% each enzyme).

The anionic detergent is a mixture of sodium dodecyl-benzene sulphonate, alternatively sodium linear alkyl-benzene-sulphonate, 6% and primary alkyl sulphate of 3%. The nonionic detergent is an ethoxylate of an approx. C13-C15

primary alcohol with 7 ethoxylate residues per mole. The zeolite builder is type A zeolite. The polymer is polyacrylic acid. The perborate bleach precursor is sodium tetraborate tetrahydrate or monohydrate. The activator is tetraacetyl-ethylenediamine. The structurant is sodium silicate. The neutral inorganic salt is sodium sulphate.

5 Detergent II:

An aqueous detergent liquid according to an embodiment of the invention is formulated to contain:

Dodecylbenzene-sulphonic acid of 16%, C12-C15 linear alcohol condensed with 7 mol/mol ethylene oxide of 7%, monoethanolamine of 2%, citric
10 acid of 6.5%, sodium xylenesulphonate of 6%, sodium hydroxide of about 4.1%, protease of 0.5%, minors and water to 100%. The pH is adjusted to a value between 9 and 10.

In other useful embodiments, the detergent compositions can be formulated as e.g. in International Patent Publications Nos. WO 91/00334, WO
15 91/00335, and International Patent Application No. PCT/DK91/00399.

The invention is further illustrated in the following examples, which are not intended to be in any way limiting to the scope of the invention as claimed.

EXAMPLE 1

Preparation Example

20 In the following Example, showing a presently preferred method for constructing and expressing genes to code for wild-type and variant protease enzymes in accordance with embodiments of the present invention, the following materials are referred to:

B. subtilis 309 and 147 are variants of *Bacillus lentus*, deposited with
25 the NCIB and accorded the accession numbers NCIB 10147 and NCIB 10309, and described in US Patent No. 3,723,250 incorporated by reference herein.

E. coli MC 1000 (M.J. Casadaban and S.N. Cohen (1980); J. Mol. Biol.; 138 179-207), was made r-,m+ by conventional methods and is also described in US Patent Application Serial No. 039,298.

A vector suited to a synthetic gene coding for subtilisin 309 and its mutants was constructed. It is essentially a pUC19 plasmid [C. Yanish-Perron and J. Messing (1985); Gene; 33 103-119], in which the multiple cloning site has been replaced by a linker containing the restriction sites used to separate the five sub-fragments constituting the gene. The new linker was inserted into Eco RI - HindIII cut pUC19 thereby destroying these sites.

(RI) KpnI PstI EcoRI Hind3 ClaI SphI Bam (H3)
 5' - AATTGGTACCCTGCAGGAATTCAAGCTTATCGATGGCATGCGGATCC - 3'
 3' - CCATGGGACGTCCTTAAGTTCTGAATAGCTACCGTACGCCTAGGTCTGA - 5'

A synthetic gene coding for the mature part of subtilisin 309 was constructed as shown by the following description and the diagrams given in Figure 1 (sheets 1/7 to 7/7) of the accompanying drawings. The structure of the synthetic gene is summarised in sheets 1/7 to 4/7, which also indicate fragments used in the construction. Each subfragment was made from 6 to 12 oligonucleotides. The oligonucleotides were synthesised on an automatic DNA synthesizer using phosphoramidite chemistry on a controlled glass support [S.L. Beaucage and M.H. Caruthers (1981); Tetrahedron Letters; 22 1859-1869]. Dots in the 5'-end of the oligonucleotides in the Figures are meant to indicate that these oligonucleotides have been phosphorylated. Duplexes (indicated in sheets 1/7 to 4/7) were formed from corresponding pairs of oligonucleotides by heating for 5 min at 90 deg C followed by cooling to room temperature over a period of 75 min. The duplexes were mixed and treated with T4 DNA ligase.

The five subfragments were isolated on a 2% agarose gel and inserted into pSX191. The sequence was verified by dideoxynucleotide sequencing. Fragments A-E were isolated and ligated together with KpnI-BamHI cut pSX191. The ligation mixtures were used to transform competent *E. coli* MC1000 r-,m+ selecting for ampicillin resistance. The 850 bp KpnI-BamHI fragment that constitutes the part

of the subtilisin 309 gene coding for the mature part of the enzyme was then used to replace the wild type gene on pSX212 giving rise to pSX222, which was then transformed into competent *B subtilis* SHa273. After fermentation of the transformed strain and purification of the enzyme it was shown that the product was indistinguish-
5 able from the wild type product.

Protease variants derived from the synthetic gene are made by using oligonucleotides with altered sequence at the place(s) where mutation is wanted (e.g. with sequences as given below) and mixing them with the rest of the oligonucleotides appropriate to the synthetic gene. Assembly of the variant gene is
10 carried out with the variant materials in a manner otherwise analogous to that described above. Further information on synthetic genes generally is available in *Agarwal et al* (1970); *Nature*; 227 27-34.

A KpnI site was introduced into the beginning of the subtilisin 309 synthetic gene encoding the mature part of the enzyme. The method used is called
15 oligonucleotide directed double-strand break repair mutagenesis and is described by *Wlodek Mandecki* (1986); *Proc. Nat. Acad. Sci. USA*; 83 7177-7181. pSX172 is opened with NcoI at the beginning of the mature part of the subtilisin 309 gene and is mixed with the oligonucleotide NOR 789 (sequence shown in Fig. 1 (7/7)), heated to 100 deg C, cooled to 0 deg C, and transformed into *E coli*. After retransfor-
20 mation, the recombinants can be screened by colony hybridisation using 32-P-labelled NOR 789. The recombinants that turned out to be positive during the screening had the KpnI site introduced right in front of NcoI by changing two bases without changing the amino acid sequence. pSX172 is described in EP Patent Publication No. 405,901. The KpnI site so created is inserted into pSX120 on a 400-bp PvuI -
25 NheI fragment, giving rise to pSX212. pSX120 is also described in EP Patent Publication No. 405,901.

The synthetic gene is inserted between KpnI and BamHI on pSX212, giving rise to pSX222.

Examples of mutations and corresponding sequences of oligonu-
30 cleotides are as follows:

A194P (fragment D3)

5' - AACAAACCGCGCTAGCTTTTCACAGTATGGCCCAGGC - 3'
 |||||
 3' - GCGCGATCGAAAAGTGTACATACCGGGTCCGGAAGT - 5'

A172P (fragment D2)

5' - CGCTATCCGAACGCAATGGCAGTCGGAGCTACTGATCAAAAC - 3'
 *|||
 3' - GGCTTGCGTTACCGTCAGCCTCGATGACTAGTTTGTGTTG - 5'

S57P (fragment B1)

10 5' - AGCTTTGTACCAGGGGAACCGCCGACTCAAGATGGG - 3'
 |||||
 3' - AACATGGTCCCCTTGGCGGCTGAGTTCTACCCTTACCC - 5'

These oligonucleotides were combined with the rest of the oligonucleotides from the synthetic gene that was not changed.

15

EXAMPLE 2Purification Example

This procedure relates to purification of a 10 litre scale fermentation of the Subtilisin 147 enzyme, the Subtilisin 309 enzyme or mutants thereof.

Approximately 8 litres of fermentation broth were centrifuged at 5000
 20 rpm for 35 minutes in 1 litre beakers. The supernatants were adjusted to pH 6.5 using 10% acetic acid and filtered on Seltz Supra S100 filter plates.

The filtrates were concentrated to approximately 400 ml using an Amicon CH2A UF unit equipped with an Amicon S1Y10 UF cartridge. The UF concentrate was centrifuged and filtered prior to absorption at room temperature on
 25 a Bacitracin affinity column at pH 7. The protease was eluted from the Bacitracin column at room temperature using 25% 2-propanol and 1 M sodium chloride in a buffer solution with 0.01 dimethylglutaric acid, 0.1 M boric acid and 0.002 M calcium chloride adjusted to pH 7.

The fractions with protease activity from the Bacitracin purification step
 30 were combined and applied to a 750 ml Sephadex G25 column (5 cm dia.) equili-

The fractions with protease activity from the Bacitracin purification step were combined and applied to a 750 ml Sephadex G25 column (5 cm dia.) equilibrated with a buffer containing 0.01 dimethylglutaric acid, 0.2 M boric acid and 0.002 M calcium chloride adjusted to pH 6.5.

5 Fractions with proteolytic activity from the Sephadex G25 column were combined and applied to a 150 ml CM Sepharose CL 6B cation exchange column (5 cm dia.) equilibrated with a buffer containing 0.01 M dimethylglutaric acid, 0.2 M boric acid, and 0.002 M calcium chloride adjusted to pH 6.5.

The protease was eluted using a linear gradient of 0-0.1 M sodium
10 chloride in 2 litres of the same buffer (0-0.2 M sodium chloride in case of sub 147).

In a final purification step protease containing fractions from the CM Sepharose column were combined and concentrated in an Amicon ultrafiltration cell equipped with a GR81PP membrane (from the Danish Sugar Factories Inc.).

EXAMPLE 3

15 Differential Scanning Calorimetry

The purified protease variants were subjected to thermal analysis by Differential Scanning Calorimetry (DSC).

The instrument was a Setaram micro DSC apparatus connected to HP86 computer for data collection and analysis. Setaram software was used.

20 The enzyme was diluted to a concentration of preferably 2 mg/ml in a liquid built detergent (pH 8.5) of the following composition:

AE ¹ (C ₁₂₋₁₄); EO 6	15 %
LAS ² (C ₁₂)	10 %
Coconut fatty acid	9 %
25 Oleic acid (C ₁₈)	1 %
Triethanolamin (pKA 7.9)	9 %
Glycerol	10.5 %
Ethanol	1.5 %
Sodium citrate	8 %

CaCl ₂ · 2H ₂ O	0.1 %
NaOH	1 %
Water	34.9 %

5 ¹) Alcohol ethoxylate

²) Linear alkylbenzene sulphonate

The heating rate was 0.5°C/min from 25°C to 90°C.

The stabilization of Subtilisin 309 variants relative to wild type enzyme measured by this method is presented in Table 3, above.

10

EXAMPLE 4

Storage Stability

The storage stability of the enzymes of the invention was determined and compared to the storage stability of subtilisin 309 (wild-type). This stability test is performed as a Mini Storage Test. In each tube 100 µl of sample were used.

15 The enzyme dosages were 0.25 mg enzyme/g detergent. A liquid detergent composition was used in this test, *vide* Detergent II, *supra*.

The tubes were incubated at 35°C for 3, 7, 14, and 21 days, respectively, and the residual activity determined.

20 The residual activity determination method was based on the digestion of a dimethyl casein (DMC) solution by the proteolytic enzymes. The primary amino groups formed in this process react with trinitrobenzene sulphonic acid (TNBS) forming a coloured complex. The reaction is followed in situ in order that the change in absorbance per time unit can be calculated.

25 Since the detergent might contain compounds with primary amino groups, it is necessary to examine this and make correction of the detergent effect. Correction is made by measuring the blind value of the pure detergent and subtracting this value from the value measured as described above.

The activity is determined relative to a sample which immediately after preparation is frozen and kept at a temperature of -10°C until analysis. The activity

of this sample is set to 100%. The activity of the corresponding samples from the storage test is determined relative to the 100% sample.

The reaction conditions were:

Temperature:	40°C
5 pH:	8.3
Wavelength:	420 nm
Reaction time:	9 min.
Measuring time:	3 min.
Apparatus:	<COBAS> FARA II centrifugal ana-
10	lyzer from Roche.

All activities were determined in duplicate.

A folder, AF 285/1 (or later editions), describing this analytical method is available upon request to Novo Nordisk A/S, Denmark, which folder is hereby included by reference.

15 The result of the storage stability test is shown in Fig. 2. In general, thermostability as determined by DSC and storage stability correlate well.

EXAMPLE 5

Wash Performance

The wash performance tests were accomplished on grass juice soiled
20 cotton in a model wash at 20°C, isothermically for 10 minutes.

As detergent 5 g/l of a powder detergent was used, *vide* Detergent I, *supra*. pH was adjusted by addition of NaOH/HCl to 10.2. The water used was approximately 9°dH (German Hardness) for the tests presented in Table 5. For the tests presented in Table 6, 6°dH water was used. The textile/wash liquor ratio was
25 6 g textile per litre of wash liquor.

Tests were performed at enzyme concentrations of: 0, 0.025, 0.05, 0.1, 0.5, 1.0, and 2.0 mg enzyme protein/l. Two independent sets of tests were performed for each of the enzymes. The results shown in Tables 5-6 are means of these tests.

Subsequent to washing, the fabric was rinsed in running tap water and air-dried. The protease performance was determined by the change (ΔR) of the remission (%R) at 460 nm measured on a Datacolor Elrephometer 2000, ΔR being the remission after wash with protease added minus the remission after wash with
 5 no protease added.

Results from the wash performance tests are presented in Tables 5-6. It is found that all the variants, except Subtilisin 309/S256P, perform at least equal to subtilisin 309 (wild-type).

Table 5

10 Differential Remission, delta R

Variant	Enzyme dosage mg enzyme/l detergent					
	0.025	0.05	0.1	0.5	1.0	2.0
15 S57P	2.4	4.4	7.4	16.8	20.0	22.1
A172P	2.4	4.4	7.5	16.9	20.1	22.3
S188P	2.2	4.8	7.5	16.9	20.9	21.7
A194P	2.5	5.3	7.6	17.5	20.5	20.8
Subt.309	3.2	4.6	6.9	16.1	20.4	20.7
20 S259P	1.7	2.5	3.9	6.7	7.2	7.0
Subt.309	0.8	2.2	3.6	5.8	6.5	6.6

Table 6

Differential Remission, delta R

s Variant	Enzyme dosage mg enzyme/l detergent					
	0.025	0.05	0.1	0.5	1.0	2.0
T38P	1.9	3.7	7.0	14.7	16.9	16.7
S99P	1.8	3.1	5.4	15.4	16.4	16.9
S258P	0.7	1.5	3.0	9.7	15.2	16.8
10 Subt.309	1.9	3.9	6.9	14.5	16.2	17.1

CLAIMS

1. A stabilized protease, in which a naturally occurring amino acid residue (other than proline) has been substituted with a proline residue at one or more positions, at which position(s) the dihedral angles ϕ (phi) and ψ (psi) constitute values within the intervals $[-90^\circ < \phi < -40^\circ$ and $-180^\circ < \psi < 180^\circ]$, preferably within the intervals $[-90^\circ < \phi < -40^\circ$ and $120^\circ < \psi < 180^\circ]$ or $[-90^\circ < \phi < -40^\circ$ and $-50^\circ < \psi < 10^\circ]$, and which position(s) is/are not located in regions, in which the protease is characterized by possessing α -helical or β -sheet structure.
2. The protease of claim 1, being a stabilized subtilisin.
3. The subtilisin of claim 2, in which the stabilized subtilisin obtained is any subtilisin which comprises a substitution into a proline residue at one or more of the positions listed in Tables 1 and 2 (BPN' numbers), or positions analogous hereto.
4. The subtilisin of claim 3, in which a naturally occurring amino acid (other than proline) has been substituted with a proline residue at one or more of the positions: 38, 57, 98, 172, 188, 194, 242, and 259 (BPN' numbers).
5. The subtilisin of claim 4, further comprising one or more of the following substitutions: 27R, 36D, 76D, 97N, 98R, 104Y, 120D, 128G, 195E, 206C, 218S, 235L, 235R, 237R, 251E, and 263F (BPN' numbers).
6. The subtilisin of either of claims 4-5, being a stabilized subtilisin 309, a stabilized subtilisin 147, a stabilized subtilisin BPN', or a stabilized subtilisin Carlsberg.
7. Subtilisin 309, in which one or more of the following substitutions have been introduced: T38P, S57P, A98P, A172P, S188P, A194P, S242P, and S259P (BPN' numbers).

8. Subtilisin 309 of claim 7, further comprising one or more of the following substitutions: K27R, *36D, N76D, G97N, A98R, V104Y, H120D, S128G, G195E, Q206C, N218S, K235L, K235R, K237R, K251E, and Y263F (BPN' numbers).
9. Subtilisin 309, in which one or more of the following substitutions have been introduced: T38P, S57P, A98P, A172P, A194P, S242P, and S259P (BPN' numbers).
10. Subtilisin 309 of claim 9, further comprising one or more of the following substitutions: K27R, *36D, N76D, G97N, A98R, V104Y, H120D, S128G, G195E, Q206C, N218S, K235L, K235R, K237R, K251E, and Y263F (BPN' numbers).
11. Subtilisin 309/K27R+*36D+G97N+A98R+A194P+K235R+K237R+K251E+Y263F (BPN' numbers).
12. Subtilisin 309/K27R+*36D+G97N+A194P+K235R+K237R+K251E+Y263F (BPN' numbers).
13. Subtilisin 309/K27R+*36D+G97N+A194P+K235R+K237R+Y263F (BPN' numbers).
14. Subtilisin 309/*36D+N76D+H120D+A194P+G195E+K235L (BPN' numbers).
15. Subtilisin 309/*36D+G97N+V104Y+H120D+A194P+G195E (BPN' numbers).
16. Subtilisin 309/*36D+G97N+V104Y+H120D+A194P+G195E+K235L (BPN' numbers).
17. Subtilisin 309/*36D+G97N+H120D+A194P+G195E (BPN' numbers).

18. Subtilisin 309/*36D+G97N+H120D+A194P+G195E+K235L (BPN' numbers).
19. Subtilisin 309/*36D+V104Y+H120D+A194P+G195E (BPN' numbers).
- 5 20. Subtilisin 309/*36D+V104Y+H120D+A194P+G195E+K235L (BPN' numbers).
21. Subtilisin 309/*36D+H120D+A194P+G195E (BPN' numbers).
22. Subtilisin 309/*36D+H120D+A194P+G195E+K235L (BPN' numbers).
- 10 23. Subtilisin 309/A194P (BPN' numbers).
24. A nucleotide sequence encoding a stabilized protease of any of claims 1-23.
25. An expression vector comprising a nucleotide sequence encoding a stabilized protease according to any of claims 1-23.
- 15 26. A host organism containing an expression vector carrying a nucleotide sequence encoding a stabilized protease of any of claims 1-23.

1/20




Fig. 1

2/20




Fig. 1

3/20




Fig. 1

4/20






Fig. 1

5/20



6/20



7/20




Fig. 1

8/20

A
 E
 LM
 IL
 Lu
 II
 /
 E5-00
 CTTGTTAACGCGAAGCGGCAACCGGTTAATCAATAAAAAACGCTGTCGGGTTAAAGGG
 781
 GAACAAATTGCGCTCTCGCCGTTGGGCAATTAGTTATTTTGGGACACGCCCAATTTCCTC
 840
 L V N A E A T R *
 275
 E6-00
 CACAGCGTTTGTGTATGgattcc
 841
 GTGTCCGCAAAAAACACATACCTAG
 866

100

9/20

Enzymes that do cut:

AccI	AflIII	AlwNI	AvaI	AvrII	BamHI	BanI	BclI
BglII	BpuII02I	BsgI	BsiEI	BspI286I	BspMI	BssHII	BstXI
BstXI	ClaI	DraI	DsaI	EaeI	Eco47III	EcoRI	EcoRV
FsiI	GdiII	HaeI	HaeII	HgiAI	HgiEII	HincII	HindIII
HpaI	KpnI	MluI	MmeI	MslI	NcoI	NdeI	NheI
NotI	NspI	NspV	NspBII	PflMI	PvuI	PvuII	SaiI
SmaI	SpeI	SphI	SspI	StuI	StyI	TaqII-1	TthIII
XbaI	XhoI	XmaIII	XmnI				

Fig. 1

10/20

Enzymes that do not cut:

AatII	AflII	AgeI	ApalI	AscI	AseI
BaeI	BalI	BanII	BcgI	BetI	BglI
BpuI0I	BsaI	BsaBI	BsaHI	BsiWI	BsmI
BspEI	BspGI	BspHI	BstEII	CfrI0I	DraIII
DrdI	DrdII	EamII05I	EclII	EcoNI	EcoO109I
Esp3I	FseI	FspI	MunI	NarI	NruI
NsiI	PacI	PflI108I	PmlI	PshAI	PstI
RleAI	RsrII	SacII	ScaI	SfiI	SgrAI
SnaBI	Sse8387I	SstI	TaqII-2	XcmI	
			TthI111I		

Fig. 1

11/20




Fig. 1

12/20




Fig. 1

13/20

KpnI PstI EcoRI Hind3 ClaI SphI BamHI
5'-AATGGTACCCTGCAGGAATTC AAGCTTATCGATGCGATCGGATCC-3'
.....
3'-CCATGGGACGCTCTTAAGTTCGAATAGCTACCGTACGCCCTAGGTCCA-5'

100

14/20




Fig. 1

15/20





Fig. 1

16/20



Identification
○ A194P + S57P * S188P ● Subtilisin 309

Fig. 2

17/20




Fig. 2

18/20





Fig. 2

19/20




Identification

-○- A172P +△ S24P * S57P ● Subtilisin 309 * Q182P

Fig. 2

20/20



+ S99P * S256P x T38P ● Subtilisin 309

Fig. 2

INTERNATIONAL SEARCH REPORT

International Application No. PCT/DK 92/00138

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ² According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 12 N 9/50, 15/57																	
II. FIELDS SEARCHED <div style="text-align: right; font-size: small;">Minimum Documentation Searched¹</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%; border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 2px;">Classification System</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px;">IPC5</div> </td> <td style="width: 70%; border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 2px;">Classification Symbols</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px;">C 12 N</div> </td> </tr> </table> <div style="text-align: center; font-size: x-small; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in Fields Searched²</div> <div style="padding: 5px; margin-top: 10px;">SE,DK,FI,NO classes as above</div>			<div style="border: 1px solid black; padding: 2px;">Classification System</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px;">IPC5</div>	<div style="border: 1px solid black; padding: 2px;">Classification Symbols</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px;">C 12 N</div>													
<div style="border: 1px solid black; padding: 2px;">Classification System</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px;">IPC5</div>	<div style="border: 1px solid black; padding: 2px;">Classification Symbols</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px;">C 12 N</div>																
III. DOCUMENTS CONSIDERED TO BE RELEVANT³ <table border="1" style="width: 100%; border-collapse: collapse; font-size: x-small;"> <thead> <tr> <th style="width: 10%;">Category *</th> <th style="width: 60%;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 30%;">Relevant to Claim No.¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td style="vertical-align: top;">WO, A1, 8901520 (CETUS CORPORATION) 23 February 1989, See especially claim 1, Cited in the application</td> <td style="text-align: center; vertical-align: top;">1,24-26</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td style="text-align: center; vertical-align: top;">---</td> <td style="text-align: center; vertical-align: top;">2-26</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td style="vertical-align: top;">WO, A1, 8909819 (GENEX CORPORATION) 19 October 1989, See especially claim 1, Cited in the application</td> <td style="text-align: center; vertical-align: top;">2-26</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td style="vertical-align: top;">WO, A1, 8705050 (GENEX CORPORATION) 27 August 1987, See especially claim 39, Cited in the application</td> <td style="text-align: center; vertical-align: top;">2-26</td> </tr> </tbody> </table>			Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	WO, A1, 8901520 (CETUS CORPORATION) 23 February 1989, See especially claim 1, Cited in the application	1,24-26	Y	---	2-26	Y	WO, A1, 8909819 (GENEX CORPORATION) 19 October 1989, See especially claim 1, Cited in the application	2-26	Y	WO, A1, 8705050 (GENEX CORPORATION) 27 August 1987, See especially claim 39, Cited in the application	2-26
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³															
X	WO, A1, 8901520 (CETUS CORPORATION) 23 February 1989, See especially claim 1, Cited in the application	1,24-26															
Y	---	2-26															
Y	WO, A1, 8909819 (GENEX CORPORATION) 19 October 1989, See especially claim 1, Cited in the application	2-26															
Y	WO, A1, 8705050 (GENEX CORPORATION) 27 August 1987, See especially claim 39, Cited in the application	2-26															
<div style="font-size: x-small;"> <p>* Special categories of cited documents:¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div>																	
IV. CERTIFICATION <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 2px;">Date of the Actual Completion of the International Search</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px;">13th August 1992</div> </td> <td style="width: 50%; border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 2px;">Date of Mailing of this International Search Report</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px; text-align: center;">1992-08-14</div> </td> </tr> <tr> <td style="border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 2px;">International Searching Authority</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px; text-align: center;">SWEDISH PATENT OFFICE</div> </td> <td style="border: none; vertical-align: top;"> <div style="border: 1px solid black; padding: 2px;">Signature of Authorized Officer</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px; text-align: center;"> Mikael Bergstrand </div> </td> </tr> </table>			<div style="border: 1px solid black; padding: 2px;">Date of the Actual Completion of the International Search</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px;">13th August 1992</div>	<div style="border: 1px solid black; padding: 2px;">Date of Mailing of this International Search Report</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px; text-align: center;">1992-08-14</div>	<div style="border: 1px solid black; padding: 2px;">International Searching Authority</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px; text-align: center;">SWEDISH PATENT OFFICE</div>	<div style="border: 1px solid black; padding: 2px;">Signature of Authorized Officer</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px; text-align: center;"> Mikael Bergstrand </div>											
<div style="border: 1px solid black; padding: 2px;">Date of the Actual Completion of the International Search</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px;">13th August 1992</div>	<div style="border: 1px solid black; padding: 2px;">Date of Mailing of this International Search Report</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px; text-align: center;">1992-08-14</div>																
<div style="border: 1px solid black; padding: 2px;">International Searching Authority</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px; text-align: center;">SWEDISH PATENT OFFICE</div>	<div style="border: 1px solid black; padding: 2px;">Signature of Authorized Officer</div> <div style="border: 1px solid black; padding: 2px; margin-top: 10px; text-align: center;"> Mikael Bergstrand </div>																

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Dialog Information Services, file 357, Biotechnology abstracts, Dialog accession no. 089398, DBA accession no. 89-07389, Balaji V N et al: "Modification of protein stability by introduction of disulfide bridges and prolines: geometric criteria for mutation sites - subtilisin enzyme engineering", & Biochem. Biophys. Res. commun. (160, 1, 109-14) 1989 ---	2-26
A	Dialog Information Services, file 5, BIOSIS, Dialog accession no. 5972320, BIOSIS no. 84104885, Piela L et al: "Proline-Induced constraints in alpha-helices", & Biopolymers 26 (9), 1987, 1587-1600 -----	1-26

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. PCT/DK 92/00138

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the Swedish Patent Office EDP file on 01/07/92. The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 8901520	89-02-23	AU-D- 2421588	89-03-09
		US-A- 5041378	91-08-20
WO-A1- 8909819	89-10-19	EP-A- 0409892	91-01-30
		JP-T- 3503604	91-08-15
		US-A- 4990452	91-02-05
WO-A1- 8705050	87-08-27	EP-A- 0260299	88-03-23
		JP-T- 63502959	88-11-02
		US-A- 4980288	90-12-25
		US-A- 4990452	91-02-05